Anthracyclines
"Anthracyclines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Descriptor ID |
D018943
|
MeSH Number(s) |
D02.455.426.559.847.562.050 D04.615.562.050 D09.408.051.059
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Anthracyclines".
Below are MeSH descriptors whose meaning is more specific than "Anthracyclines".
This graph shows the total number of publications written about "Anthracyclines" by people in this website by year, and whether "Anthracyclines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 | 2007 | 1 | 0 | 1 | 2008 | 0 | 1 | 1 | 2009 | 2 | 1 | 3 | 2010 | 0 | 1 | 1 | 2012 | 1 | 1 | 2 | 2013 | 1 | 1 | 2 | 2014 | 2 | 1 | 3 | 2015 | 1 | 0 | 1 | 2016 | 1 | 0 | 1 | 2018 | 0 | 1 | 1 | 2019 | 1 | 0 | 1 | 2020 | 0 | 2 | 2 | 2021 | 0 | 1 | 1 | 2022 | 0 | 3 | 3 | 2023 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Anthracyclines" by people in Profiles.
-
Roy S, Lakritz S, Schreiber AR, Kuna EM, Bradley CJ, Kondapalli L, Diamond JR. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study. Eur J Cancer. 2024 Jan; 196:113426.
-
Wang Y, Ronckers CM, van Leeuwen FE, Moskowitz CS, Leisenring W, Armstrong GT, de Vathaire F, Hudson MM, Kuehni CE, Arnold MA, Demoor-Goldschmidt C, Green DM, Henderson TO, Howell RM, Ehrhardt MJ, Neglia JP, Oeffinger KC, van der Pal HJH, Robison LL, Schaapveld M, Turcotte LM, Waespe N, Kremer LCM, Teepen JC. Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nat Med. 2023 09; 29(9):2268-2277.
-
Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Wood M, Elias A, Kondapalli L, Bradley CJ, Diamond JR. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer. 2023 05; 185:69-82.
-
Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho GY, Popescu BA, Kosmala W, Costello B, la Gerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E, Banchs J, Kutty S, Negishi K, Marwick TH. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic?Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023 03; 16(3):269-278.
-
Maurer GS, Clayton ZS. Anthracycline chemotherapy, vascular dysfunction?and cognitive impairment: burgeoning topics and future directions. Future Cardiol. 2023 09; 19(11):547-566.
-
Clayton ZS, Ade CJ, Dieli-Conwright CM, Mathelier HM. A bench to bedside perspective on anthracycline chemotherapy-mediated cardiovascular dysfunction: challenges and opportunities. A symposium review. J Appl Physiol (1985). 2022 12 01; 133(6):1415-1429.
-
Schreiber AR, Kagihara J, Eguchi M, Kabos P, Fisher CM, Meyer E, Molina E, Kondapalli L, Bradley CJ, Diamond JR. Evaluating anthracycline?+?taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study. Breast Cancer Res Treat. 2022 Jan; 191(2):389-399.
-
Gillman AS, Vo JB, Nohria A, Ferrer RA. Decision Science Can Inform Clinical Trade-Offs Regarding Cardiotoxic Cancer Treatments. JNCI Cancer Spectr. 2021 08; 5(4).
-
Thom? CH, Ferreira GA, Pereira-Martins DA, Dos Santos GA, Ortiz CA, de Souza LEB, Sobral LM, Silva CLA, Scheucher PS, Gil CD, Leopoldino AM, Silveira DRA, Coelho-Silva JL, Traina F, Koury LC, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Nunes EC, Fagundes EM, Gloria ABF, Kerbauy FR, Chauffaille ML, Keating A, Tallman MS, Ribeiro RC, Dillon R, Ganser A, L?wenberg B, Valk P, Lo-Coco F, Sanz MA, Berliner N, Fa?a VM, Rego EM. NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Sci Rep. 2020 06 25; 10(1):10315.
-
Graffagnino J, Kondapalli L, Arora G, Hawi R, Lenneman CG. Strategies to Prevent Cardiotoxicity. Curr Treat Options Oncol. 2020 04 08; 21(4):32.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|